AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33915788
Drug: Modified low-protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified low-protein formula (mLP) (1.7 g protein/100 kcal)
Trial: 33915788
Drug: Control formula
RxNorm normalized name: Anti Acne Control Formula Top
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control formula (CTRL) (2.1 g protein/100 kcal)
Trial: 33306026
Drug: Drink Less
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drink Less app with daily 11 AM notification
Trial: 35128872
Drug: Routine western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine western medicine treatment and enema with tuihuang mixture
Trial: 34383222
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 7% sodium chloride solution
Trial: 32249850
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg lutein supplementation (beeswax group)
Trial: 32249850
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg lutein supplementation (glycerol fatty acid esters group)
Trial: 35378068
Drug: Alirocumab (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alirocumab (75 mg by subcutaneous injection every 2 weeks)
Trial: 32758455
Drug: Debio 1143
RxNorm normalized name: DEBIO-1347
DrugBank: DEBIO-1347 (DB12903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Debio 1143 (200 mg per day on days 1-14 of 21-day cycles, for three cycles)
Trial: 32758455
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 mg/mL, administered at the same dosing schedule)
Trial: 38175837
Drug: Community-wide mass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-wide mass drug administration (cMDA)
Trial: 34753540
Drug: High-dose caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose caffeine (10 mg/kg maintenance dose)
Trial: 34753540
Drug: Low-dose caffeine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose caffeine (5 mg/kg maintenance dose)
Trial: 33826415
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with IPC plus LLLT
Trial: 33826415
Drug: IPC therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPC therapy alone
Trial: 37023069
Drug: Cost-effectiveness of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost-effectiveness of treatment
Trial: 32648397
Drug: Needle-knife therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle-knife therapy at cervical spine area, acupuncture at specific acupoints, sodium hyaluronate eye drops (1 drop 5-6 times a day) for 3 courses (1 week each).
Trial: 33637882
Drug: Low-dose decitabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose decitabine (DAC) 20 mg/m2/d, i.v. for 5 days followed by modified Busulfan-Cyclophosphamide (Bu-Cy)
Trial: 33637882
Drug: Low-dose decitabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose decitabine (DAC) 20 mg/m2/d, i.v. for 5 days followed by modified Busulfan-Cyclophosphamide (Bu-Cy) in patients with active disease
Trial: 34598692
Drug: HOP‐UP‐PT program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HOP‐UP‐PT program (Home‐based Older Persons Upstreaming Prevention‐Physical Therapy) delivered by physical therapists over nine encounters (six in-person, three telerehabilitation) spanning seven months.
Trial: 32583295
Drug: Oliceridine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oliceridine (all doses)
Trial: 35196591
Drug: 0.1% nepafenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% nepafenac eye drops, thrice daily for 2 weeks
Trial: 35196591
Drug: 0.09% bromfenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.09% bromfenac eye drops, twice daily for 2 weeks
Trial: 32112591
Drug: Intralesional 5‐fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional 5‐fluorouracil (5‐FU) injections
Trial: 32112591
Drug: Both 5‐FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both 5‐FU and TAC injections
Trial: 34677593
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg methylprednisolone
Trial: 32469388
Drug: HIGH protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIGH protein diet (1.6 g protein/kg/d)
Trial: 32469388
Drug: LOW protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOW protein diet (0.5 g protein/kg/d)
Trial: 32469388
Drug: NO protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO protein diet (0.15 g protein/kg/d)
Trial: 32469388
Drug: Daily MyoPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily MyoPS rates during immobilization
Trial: 32732142
Drug: Inactivated trivalent
RxNorm normalized name: influenza virus vaccine, inactivated trivalent intradermal suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated trivalent influenza vaccine (IIV3-BV)
Trial: 32732142
Drug: Inactivated trivalent
RxNorm normalized name: influenza virus vaccine, inactivated trivalent intradermal suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated trivalent influenza vaccine (IIV3-BY)
Trial: 34118255
Drug: Preparation up
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation up to size 25.04
Trial: 34118255
Drug: Preparation up
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation up to size 25.06
Trial: 34118255
Drug: Preparation up
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation up to size 30.04
Trial: 34118255
Drug: Preparation up
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation up to size 30.06
Trial: 34118255
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no preparation in the MM canal)
Trial: 32947474
Drug: Antithrombin supplementation
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin supplementation (treatment group)
Trial: 34621054
Drug: PGT121 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGT121 at 3, 10 and 30 mg kg-1
Trial: 34621054
Drug: PGT121 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PGT121 at 30 mg kg-1
Trial: 35267206
Drug: Mailed nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mailed nicotine replacement therapy (NRT) and Quitline support
Trial: 34117385
Drug: Transconjunctival (Tconj)
RxNorm normalized name: Neisseria meningitidis serogroup A capsular polysaccharide tetanus toxoid protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transconjunctival (Tconj) local anaesthetic administration
Trial: 34117385
Drug: Transcutaneous (Tskin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous (Tskin) local anaesthetic administration
Trial: 33737646
Drug: Iron supplement
RxNorm normalized name: Iron supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplement
Trial: 34088513
Drug: Oral metronomic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metronomic therapy with etoposide (50 mg, day 1 to 14) and cyclophosphamide (50 mg, day 1 to 28, every 4 weeks)
Trial: 34088513
Drug: Pazopanib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib (400 mg once daily) in addition to etoposide and cyclophosphamide
Trial: 34088513
Drug: Oral metronomic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metronomic therapy with etoposide and cyclophosphamide
Trial: 32766862
Drug: Direct to
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct to consumer referral pathway (e.g., digital and print media, registry emails)
Trial: 32766862
Drug: Other referral
RxNorm normalized name: teferrol
DrugBank: Iron polymaltose (DB15763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other referral approaches (e.g., presentations, word of mouth)
Trial: 33559816
Drug: Solution-oriented counseling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution-oriented counseling
Trial: 32389457
Drug: Self-injected subcutaneous
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-injected subcutaneous depot medroxyprogesterone acetate (DMPA-SC)
Trial: 32389457
Drug: Provider-administered subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provider-administered subcutaneous depot medroxyprogesterone acetate (DMPA-SC)
Trial: 32389457
Drug: Self-injected and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-injected and provider-administered subcutaneous depot medroxyprogesterone acetate (DMPA-SC)
Trial: 36178914
Drug: Traditional foods
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional foods index (measured as weekly servings of traditional food consumption divided by total foods reported)
Trial: 33318391
Drug: Daily salt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily salt intake estimated using the INTERSALT equation from morning spot urine samples.
Trial: 33231866
Drug: Gemcitabine (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1000 mg/m2 on days 1 and 8) + Pazopanib (800 mg daily)
Trial: 33231866
Drug: Gemcitabine (900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (900 mg/m2 on days 1 and 8) + Docetaxel (100 mg/m2 on day 8)
Trial: 34789450
Drug: CAL-assisted PDT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAL-assisted PDT (calcipotriol applied daily for 15 days beforehand)
Trial: 39265124
Drug: Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice of chemotherapy (ICC)
Trial: 33432646
Drug: Rule-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rule-based treatment planning
Trial: 34653732
Drug: Nanocurcumin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanocurcumin (80 mg capsule daily for 8 weeks)
Trial: 35302529
Drug: Motor imagery
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Motor imagery + action observation therapy
Trial: 35302529
Drug: Mixed therapy
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed therapy (cognitive training + motor imagery + action observation therapy)
Trial: 34374847
Drug: Hypnosis-derived communication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnosis-derived communication (HC) administered by trained nurses during outpatient chemotherapy.
Trial: 33199422
Drug: Sodium selenate
RxNorm normalized name: Sodium Selenate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium selenate (15 mg three times a day)
Trial: 35697435
Drug: Cognitive Behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavior Therapy (CBGT)
Trial: 35589674
Drug: Combined paracetamol-dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combined paracetamol-dexamethasone
Trial: 35338648
Drug: Restricted IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restricted IV fluid therapy
Trial: 37330928
Drug: Standard IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard IV fluid therapy
Trial: 33538030
Drug: Epidural anesthesia
RxNorm normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural anesthesia (preservative free morphine sulfate, 0.09 mg/kg; 1% ropivacaine, 0.2 mg/kg; total volume delivered, 1 mL/4.5 kg of body weight to a maximum of 10 mL; n = 9)
Trial: 32171875
Drug: Conventional root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional root canal therapy (Group I)
Trial: 32171875
Drug: Conventional root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional root canal therapy combined with antimicrobial PDT (Group II)
Trial: 33610421
Drug: L-arginine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (3 gr/d for 10 weeks)
Trial: 32282100
Drug: Vyxeos (daunorubicin-cytarabine)
RxNorm normalized name: Vyxeos
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vyxeos (daunorubicin-cytarabine) liposome injection
Trial: 36294856
Drug: Erector Spinae
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erector Spinae Plane Block (ESPB) using 20 mL of 0.5% ropivacaine bilaterally
Trial: 35244061
Drug: Bojungikgi-tang (BJT)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bojungikgi-tang (BJT) granules administered twice a day for 8 weeks
Trial: 35771533
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal cannula/long-term oxygen therapy
Trial: 34253233
Drug: 5-ALA HCl
RxNorm normalized name: 5-ALA
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-ALA HCl 15 mg/kg
Trial: 34253233
Drug: 5-ALA HCl
RxNorm normalized name: 5-ALA
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-ALA HCl 30 mg/kg
Trial: 32803636
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea supplements (1 g twice daily; containing 300 mg EGCG)
Trial: 33822033
Drug: Spironolactone (25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (25-50 mg/day)
Trial: 33797983
Drug: Delayed-Release and
RxNorm normalized name: lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed-Release and Extended-Release Methylphenidate (DR/ER-MPH)
Trial: 33303428
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (1 to 3 sessions at intervals of one per week)
Trial: 33303428
Drug: Corticosteroid injections
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injections (1 mL of Diprostène via ultrasound-guided injection)
Trial: 35041046
Drug: Extruded rice
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extruded rice snacks containing 400 mg DHA from cauliflower-encapsulated HiDHA® algal oil
Trial: 35041046
Drug: Soup containing
RxNorm normalized name: MALT SOUP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soup containing 400 mg DHA from cauliflower-encapsulated HiDHA® algal oil
Trial: 35041046
Drug: Gel capsules
RxNorm normalized name: Dried Aluminum Hydroxide Gel Capsules
DrugBank: Sepia esculenta bone (DB16562)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gel capsules containing HiDHA® algal oil
Trial: 33046619
Drug: Mexiletine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine (150 mg 3 times daily)
Trial: 34148351
Drug: Apixaban or
RxNorm normalized name: apixaban Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban or rivaroxaban (direct acting oral anticoagulation)
Trial: 32957929
Drug: Sufentanil plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil plasma target concentration 0.0 ng ml-1 (Group S0)
Trial: 32957929
Drug: Sufentanil plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil plasma target concentration 0.1 ng ml-1 (Group S1)
Trial: 32957929
Drug: Sufentanil plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil plasma target concentration 0.3 ng ml-1 (Group S2)
Trial: 32957929
Drug: Sufentanil plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil plasma target concentration 0.5 ng ml-1 (Group S3)
Trial: 32957929
Drug: Sufentanil plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil plasma target concentration 0.7 ng ml-1 (Group S4)
Trial: 32229523
Drug: Accelerated partner
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated partner therapy (APT)
Trial: 34337507
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (group B)
Trial: 33371995
Drug: Nurse Administered
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse Administered Propofol Sedation (NAPS)
Trial: 33190147
Drug: Omega-3 carboxylic
RxNorm normalized name: omega-3 carboxylic acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 carboxylic acid (4 g/d)
Trial: 38486192
Drug: Dignity Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dignity Therapy (DT)
Trial: 33603939
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL of 0.375% ropivacaine with 100 ng of naloxone
Trial: 34652445
Drug: β-lactam (amoxicillin-clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-lactam (amoxicillin-clavulanate [1 g/125 mg] 3 times daily) for 5 extra days
Trial: 32305106
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g TXA
Trial: 33685237
Drug: Pulsed high-intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed high-intensity laser therapy (HILT)
Trial: 32799792
Drug: Ketorolac tromethamine
RxNorm normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac tromethamine 0.5 mg/kg intravenously
Trial: 34085287
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine (CHM)
Trial: 38485487
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no inhaled NO)
Trial: 33512943
Drug: 3 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 sessions of radial extracorporeal shockwave therapy (rESWT) at the 'recommended'/'maximally comfortably tolerated' dose
Trial: 33512943
Drug: 3 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 sessions of radial extracorporeal shockwave therapy (rESWT) at 'minimal dose'
Trial: 33512943
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (recommended dose and minimal dose)
Trial: 33512943
Drug: 3 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 sessions of rESWT (both doses)
Trial: 35510753
Drug: Intense pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense pulsed light (IPL) combined with minocycline (100 mg per day for 8 weeks)
Trial: 35510753
Drug: Minocycline only
RxNorm normalized name: Minocycline only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline only (100 mg per day for 8 weeks)
Trial: 35893347
Drug: Scrambler Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scrambler Therapy (ST)
Trial: 36072252
Drug: Control (pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (pain management drugs following the WHO analgesic ladder)
Trial: 33120777
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) combined with antidepressants
Trial: 34287979
Drug: Glepaglutide 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glepaglutide 0.1 mg and 1 mg
Trial: 33721562
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin 1.8 mg/kg intravenously every 3 weeks
Trial: 34261908
Drug: Short-course antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course antibiotic therapy (7 days or less) after removal of the central venous catheter (CVC)
Trial: 36369798
Drug: Deucravacitinib 3
RxNorm normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deucravacitinib 3 mg twice daily
Trial: 36369798
Drug: Deucravacitinib 6
RxNorm normalized name: deucravacitinib 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deucravacitinib 6 mg twice daily
Trial: 39283417
Drug: Deucravacitinib 12
RxNorm normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deucravacitinib 12 mg once daily
Trial: 36369798
Drug: Deucravacitinib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deucravacitinib (all doses)
Trial: 35714812
Drug: GSK3389404 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3389404 (60 mg weekly)